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Abstract
Progress in radiation oncology requires a re-evaluation of the methods of target volume delineation beyond anatomical
localization. Newmolecular imaging techniques for tumour visualisation such as positron emission tomography (PET)
provide insight into tumour characteristics and can be complementary to the anatomical data of computed tomography
or magnetic resonance imaging. In this review, three issues are discussed: First, can PET identify a tumour more
accurately? Second, can biological tumour characteristics be visualised? Third, can intratumoural heterogeneity of
these characteristics be identified?
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Introduction
In the past decade, there has been substantial techno-
logical progress in radiation oncology. Dose delivery
with high geometric precision is possible due to the
introduction of stereotactic radiotherapy, radiosurgery,
intensity modulated radiotherapy (IMRT) and three-
dimensional planning of brachytherapy. These develop-
ments require a re-evaluation of the standard methods for
target volume delineation. The current standard of target
volume definition is based on information gathered by
physical examination, computed tomography (CT) and
magnetic resonance imaging (MRI). In recent years new
methods for tumour visualisation have been introduced in
oncology. Imaging techniques such as positron emission
tomography (PET), single-photon emission computed
tomography (SPECT) and magnetic resonance spec-
troscopy (MRS) are able to visualise biological character-
istics of tumours, providing information on metabolism,
physiology and molecular biology of tumour tissue.
These so-called ‘functional’ or ‘molecular’ imaging
modalities complement the anatomical data supplied by
CT andMRI and include several potential advances. First,
the primary tumour can be identified more accurately. If
carefully validated this could resize and reshape the gross
tumour volume (GTV). This consequently could increase
cure rates by reducing the chance of geographically
missing part of the tumour during the treatment. When
imaging modalities become more accurate, the inter- and
intraobserver variation in tumour delineation decreases,
which implies an enormous increase in the standard
of care. More accurate tumour identification could also
lead to an increased normal tissue sparing. Second,
tumour characteristics relevant for radiation sensitivity
can be visualised. Functional imaging may identify the
degree of radiosensitivity of tumours, leading to an
individualization of the radiation treatment. For example,
the addition of a hypoxic cell sensitiser like nimorazole
could be advantageous for radiation treatment when the
tumour demonstrates a certain level of hypoxia [1]. Third,
intratumoural biological heterogeneity can be identified.
Ling et al. [2] introduced the concept of ‘biological target
volume’. This biological target volume represents a
subvolume of the tumour with specific characteristics on
functional or molecular imaging techniques. Subvolumes
that are relatively resistant to radiation receive an extra
dose delivered with high precision on a small volume,
which is called ‘dose painting’ or ‘dose sculpting’. This
could increase cure rates without increasing the chances
of late radiation-induced toxicity.
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In this review we focus on PET as this molecular
imaging technique is becoming widely available at an
astonishing rate. Significant clinical work has already
been done to investigate its possible role in radiation
treatment planning. The following three issues are
discussed:
(1) Can PET identify the primary tumour more
accurately?
(2) Can biological tumour characteristics be visu-
alised?
(3) Can intratumoural biological heterogeneity be
identified?
Can PET identify the primary tumour
more accurately?
Co-registration
CT is the reference imaging modality for radiation
treatment planning as it provides electron density
information of the various tissues which is needed for
the dose calculation algorithms. However, CT images
lack contrast between soft tissue structures and tumour
extension. For example, the assessment of oral cavity and
oropharyngeal tumours is severely hampered by scatter
artefacts of dental fillings. Compared to CT, MRI has
shown to be more accurate in evaluating soft tissue and
can be more sensitive for bone invasion of head and
neck tumours, but it also has its limitations, such as
geometric distortions at field of view edges, and artefacts
at interfaces of bone and air.
The observation that malignant tumour cells are
characterised by increased glycolysis resulted in the
development of whole body imaging using PET and the
fluorine-18 labelled glucose analogue fluorodeoxyglu-
cose (FDG). The high sensitivity of FDG-PET is related
to the upregulation of glucose transporters on the cell
membrane as well as increased hexokinase activity in a
wide variety malignancies [3]. Following phosphorylation
by hexokinase, FDG is trapped in cells and leads to an
uptake into tissue in proportion to the overall glucose
metabolism. FDG uptake, however, is not cancer-specific,
as increased glucose metabolism is also seen in inflam-
matory processes, muscle activity and brain activity.
To incorporate PET data into CT-based tumour
delineation there are three options of image fusion: visual
fusion, where the physician compares two separate imag-
ing modalities viewed next to each other, software fusion,
where both modalities acquired on separate machines are
overlaid in an integrated set of images (co-registration),
and hardware fusion in which both data sets are acquired
on one single machine, e.g. a hybrid PET/CT scanner.
The co-registration of CT (and/or MRI) and PET
images has successfully been demonstrated by many
groups [4–6]. If performed properly, co-registration
matches the performance of a hybrid PET/CT [6].
Validation
In 2005 Ng et al. [7] reported on 124 patients with
cancer of the oral cavity, all eligible for surgery. Non
co-registered FDG-PET and CT or MRI were obtained
to determine their performance in detecting the primary
tumour with histopathology as the gold standard. This,
the largest study to date, confirmed earlier data showing
that 122 of 124 tumours were correctly detected by
FDG-PET versus 108 on CT or MRI. FDG-PET missed
a small superficial tumour and misinterpreted a floor
of mouth tumour for a tongue tumour. However, no
attempt was made to accurately delineate the tumour.
The best evidence to date that FDG-PET can identify
the primary tumour in head and neck cancer more
accurately than conventional imaging is provided by
Daisne et al. [8]. They compared the role of co-registered
CT, MRI and FDG-PET in delineating the primary
tumour in nine patients with laryngeal cancer who
were scheduled for laryngectomy. Compared to the
reference surgical specimen, all modalities overestimated
the extension of the tumour. The average GTV on
histological examination was 12.6 cm3, whereas averages
for the various imaging modalities were 16.3 cm3 (PET),
20.8 cm3 (CT) and 23.8 cm3 (MRI). PET was closest
to depict the true tumour volume, but all three imaging
modalities (including PET) failed to identify a small
fraction (approximately 10%) of the macroscopic tumour,
mainly superficial mucosal extension.
Application of radiopharmaceuticals other than FDG
which depict different characteristics of tumour cells
may also play a role in accurate tumour defini-
tion, e.g. the amino acid based radiopharmaceuticals
O-[2-18F fluoroethyl]-L-tyrosine (FET) and [methyl-
11C]methionine (MET). In brain tumour imaging FET
and MET both have an advantage over FDG, as they
do not accumulate in normal brain cells. FET-PET was
superior in delineating human gliomas compared with
MRI, which was demonstrated by the use of stereotactic
biopsies in 28 glioma patients [9]. When comparing FET-
PET to FDG-PET and CT in 18 patients with head and
neck cancer, both FET-PET and FDG-PET were superior
to CT in the detection of tumour [10]. FET-PET showed
no uptake in physiologic tissue and inflammatory tissue,
resulting in a higher specificity for tumour detection
than FDG-PET. A drawback of FET-PET was a lower
sensitivity, caused by a relatively low tumour uptake
compared to FDG-PET.
MET-PET images in patients with brain tumours were
investigated by correlating MET uptake with histological
examination of stereotactic biopsies [11]. Solid parts of
brain tumours as well as brain tissue with infiltrating
tumour cells were detected with high sensitivity (87%)
and specificity (89%). Kracht et al. [11] emphasized its
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Figure 1 Planning CT scan (A), corresponding FDG-PET scan (B) and fusion image (C) show differences in
target volume definition. Volume GTV CT (red) = 47.5 cm3, GTV VIS (green) = 43.8 cm3, GTV 40% (yellow)
= 20.1 cm3, GTV 2.5 (orange) = 32.6 cm3, GTV UCL (blue) = 15.7 cm3. Note that GTV UCL is significantly
smaller than GTV CT and GTV VIS.
value as a delineation tool for treatment planning in
neurosurgery and radiotherapy. Grosu et al. [12] investi-
gated the role of MET-PET in target volume definition of
meningeoma patients. In skull-base tumours they found
MET-PET to be superior in defining tumour infiltration
in the surrounding structures compared to CT/MRI. Fur-
thermore, they demonstrated that MET-PET significantly
decreased the interobserver variability in tumour delin-
eation as compared to CT/MRI-based delineation [13].
Reduction of interobserver variability
Interobserver variability of radiation target volume
definition is a widely recognized problem. In laryngeal
cancer for example, target definition using only CT
leads to significant inter- and intraobserver variations in
delineation of the GTV [14].
When imaging modalities become more accurate, the
interobserver variability will decrease. A reduction in the
interobserver variability is seen by incorporating FDG-
PET data in the treatment planning [13,15–18]. Ciernik
et al. [17] reported a reduction in the mean volume
difference of 26.6 cm3 to 9.1 cm3 when FDG-PET was
incorporated into the CT-based GTV definition of 39
patients with various solid tumours. This was associated
with a reduction of the standard deviation from 38.6
cm3 to 14.4 cm3. For 30 patients with NSCLC Caldwell
et al. [16] found a large variation in GTVs between the
observers. The mean ratio of largest to smallest GTV
was 2.31 when CT based and 1.56 when PET-CT based,
indicating a clear improvement. When analysing target
definition of 22 patients with NSCLC by 11 observers,
Steenbakkers et al. [18] found that the amount of
disagreement was reduced from 45% (CT based) to 18%
(PET-CT based). Ashamalla et al. [15] reported that for 19
patients with NSCLC the interobserver GTV variability
decreased from a mean volume difference of 28.3 cm3
(CT based) to 9.1 cm3 (PET-CT based), with a respective
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Figure 2 Planning CT (A), corresponding FDG-PET (B) and fusion image (C) show differences in target
volume definition. PET activity in the air cavity is also illustrated.
decrease in standard deviation from 20.99 to 6.47. Co-
registration of CT and FDG-PET reduces this variability
even further, which was demonstrated in NSCLC by
comparing co-registered to non-registered images [19].
Thresholding
Studies comparing GTV definition using FDG-PET
(GTVpet) and T1 weighted contrast enhanced MRI
(GTVmri) in high-grade astrocytomas consistently
showed that GTVpet was smaller than GTVmri [20,21].
Similar studies comparing GTVpet to delineation using
CT or MRI (GTVct/mri) have been performed in head
and neck cancer [17,22–26]. Results show either no differ-
ence between GTVs or that GTVpet was significantly
smaller than GTVct/mri. A reason for this might be that
the optimal way to delineate a tumour on PET is not
clearly defined, resulting in variations in the methods
for defining GTVpet. In clinical nuclear medicine, PET
studies are usually interpreted qualitatively, whilst in
radiation oncology a more quantitative approach is
necessary as edge detection is required for tumour
contouring [27].
PET images can be interpreted by visual assessment
only (GTVvis), or by choosing thresholds, i.e. segment-
ing a lesion on the basis of a given level of radioactivity.
This threshold could be any fixed cut-off of the
standardized uptake value (SUV), and some investigators
choose a cut-off of 2.5 (GTV2.5) [28,29]. Thresholds are
more commonly defined as a fixed percentage of the
maximum tumour activity, for example 40% (GTV40%).
Erdi et al. [30] performed two-dimensional analyses of
phantom experiments and stated that a threshold between
36% and 44% of the maximum activity would lead to an
adequate segmentation. Ciernik et al. [17] recommended
a fixed threshold of 50% of the maximum activity,
also based on phantom data. A more sophisticated
method developed at the University St Luc (UCL) in
Brussels uses an adaptive threshold based on the signal-
to-background ratio (GTVucl) [31,32]. This method aims to
incorporate specific PET imaging properties by deriving
a mathematical function from phantom-measurements
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of objects of various sizes under various signal-to-
background conditions.
Nestle et al. [28] recently compared these four PET
delineation methods in 25 NSCLC patients. They
observed substantial differences in the resulting GTVs
and demonstrated that the choice of a tool for target
volume definition based on PET images is far from trivial.
Examples of two cases where different delineation
tools were applied are given in Figs. 1 and 2.
Site specific issues
If a lung tumour causes atelectasis, it becomes extremely
difficult to define the actual tumour on CT. In this
situation most radiation oncologists would, when in
doubt, prefer to define a larger target volume and
possibly encompass part of the atelectasis rather than
risk missing part of the tumour with a smaller target
volume. FDG-PET may assist in more accurate definition
of the border between tumour and atelectasis. This
potential application of FDG-PET needs to be validated
by resection specimen analysis. If this is proven to be
reliable, radiation oncologists will confidently delineate
a smaller target than they have done in the past. This
can potentially result in a reduction of pulmonary toxicity
by reducing the mean lung dose in patients currently
eligible for high dose radiotherapy [33]. It also means
that patients who previously were not eligible for this
treatment because of pre-existent impaired pulmonary
function, could then become eligible as a result of
the reduction in expected radiation damage to the
lung.
Several issues need to be addressed when using
FDG-PET in radiation treatment planning of NSCLC.
Although most primary NSCLC are visualized with
FDG-PET, bronchoalveolar carcinoma shows limited or
no increased FDG-uptake [34,35]. Furthermore, a post-
obstruction pneumonia may also cause increased FDG
accumulation, while malignant mediastinal involvement
can be missed in those patients with relatively high FDG
uptake in the heart. Issues associated with organ motion
have already been addressed for CT scanning by gating
image acquisition to the respiratory cycle. Similarly, it
is possible to gate the linear accelerator. Gating the
PET acquisition is also possible but experience is still
relatively limited [36,37].
In head and neck cancer, FDG-PET may miss small
lesions with insufficient tumour cells to delineate the
tumour, e.g. in superficial tumour infiltration of the
mucosal lining [8] or micrometastatic disease in the
regional lymph nodes. False positive findings can occur in
inflammatory lymph nodes, tonsils, salivary glands and in
areas of muscle activity (soft palate, base of tongue) [38].
When using segmented PET to delineate head and neck
cancer, the GTV may become artificially enlarged by an
inherent enclosure of part of an air cavity (Fig. 2). This
needs to be corrected by using the CT as the anatomical
template and subsequently ‘trimming’ part of the GTVpet
which is clearly in an air cavity. Thus, integration of
FDG-PET into target volume definition is not trivial,
but feasible. The GTVpet generally is smaller than the
GTVct or GTVmri for the primary tumour. However,
accuracy for primary tumour delineation has only been
fully validated for nine laryngeal cancers. Further studies
need to elucidate the best methodology for FDG-PET
based tumour delineation.
Figure 3 Influence of tumour oxygenation on
outcome after radiotherapy for head and neck
cancer. Tumour hypoxia was measured by administer-
ing pimonidazole followed by immunohistochemical
staining. High pimonidazole binding (low oxygen
tension) was associated with significantly worse
outcome. Reprinted with permission from Kaanders
et al. [40].
Can biological tumour characteristics
be visualized?
Relevant factors for treatment outcome
Tumour hypoxia is a strong contributor to radiation
resistance [39]. Kaanders et al. [40] correlated the hypoxic
fraction measured by staining tumour biopsies with
pimonidazole, an exogeneous hypoxia marker, with loco-
regional tumour control after radiotherapy of advanced
head and neck cancer [40]. Tumour control inversely
correlated with the hypoxic fraction (Fig. 3). Overgaard
et al. [1] demonstrated in a large randomised placebo
controlled trial that administration of the hypoxic cell
radiosensitiser nimorazole to radiotherapy could improve
loco-regional control and disease free survival in patients
with head and neck cancer.
Various treatment modifications are available to coun-
teract hypoxia induced radioresistance: irradiating during
hyperoxic gas breathing under normobaric or hyperbaric
conditions, adding a hypoxic cell sensitiser (nimorazole)
or a hypoxic cytotoxin (tirapazamine), or increasing the
radiation dose. To various extents these modifications
lead to increased toxicity. As not every patient benefits
from these treatment intensifications, careful selection of
patients is necessary, and PET could be of value as a
predictive tool.
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Another tumour characteristic associated with radiore-
sistance is tumour cell proliferation, especially in
squamous cell carcinomas. This can be counteracted by
shortening the overall treatment time, which has been
shown to be effective in several randomised clinical
trials [41,42]. As this is also a treatment intensification,
PET could possibly help in selecting patients by
identifying highly proliferating tumours, and thereby
spare those patients who are not likely to benefit from
the increased toxicity [43].
Epidermal growth factor receptor (EGFR) inhibition is
another strategy to counteract tumour cell proliferation.
EGFR plays a key role in cellular proliferation of
head and neck cancer, and Bentzen et al. [44] recently
discovered that the amount of EGFR expression in
tumour biopsies could reliably be used to select the dose
fractionation scheme that had the greatest chance of ben-
efiting the patient. Bonner et al. [45] reported that adding
an EGFR-inhibitor (cetuximab) to the radiation treatment
in a randomised clinical trial resulted in increased tumour
control with only limited increase of toxicity.
Which radiopharmaceuticals are available to
image these aspects?
For imaging of tumour hypoxia both imidazole-
and nonimidazole-containing agents have been
developed. Imidazole containing radiopharmaceu-
ticals are [18F]fluoromisonidazole (FMISO) and
[123I]iodoazomycin arabinoside (IAZA). Non-
imidazole tracers are 99mTc 4,9-diaza-3,3,10,10-
tetramethyldodecan-2,11-dione-dioxime (99mTc HL91)
and 64Cu-diacetyl-bis(N -4-methylthiosemicarbazone)
(64Cu-ATSM).
Cell proliferation can be identified by labelling DNA
precursors like thymidine or deoxyuridine, which are
incorporated in DNA replication during the S phase
of cycling cells. Clinical studies show a correlation
between 3-deoxy-3-[18F]fluorothymidine (FLT) uptake
and the Ki-67 labelling index. The latter is an accepted
immunohistochemical marker to measure prolifera-
tion [46,47]. Further clinical validation of FLT against
histopathological standards is in progress. At present,
new radiopharmaceutical are developed in the preclinical
phase to quantify tumour EGFR expression with PET, e.g.
Ga-68-EGF and Zr-89- cetuximab [48,49].
Validation
FMISO was shown to bind selectively to hypoxic cells
at radiobiologically relevant oxygen levels [50]. Piert
et al. [51,52] demonstrated in pigs that FMISO retention
occurred at relevant pO2 levels after restricting blood
supply to part of the liver. pO2 levels were measured
using invasive oxygen-sensitive Eppendorf histograph
needle electrodes. In patients, hypoxia can also be
detected by the exogenous marker pimonidazole. Biore-
duction and irreversible binding of this marker occurs
at pO2 levels below 10 mmHg and can be visualised
by immunohistochemistry in tumour sections [53]. To
validate the usefulness of FMISO for detection of
hypoxia in human tumours, Troost et al. [54] compared
FMISO autoradiography with pimonidazole immuno-
histochemistry in xenografted human squamous cell
carcinomas and glioblastomas under various conditions
of oxygen supply. They found a significant correlation
between the pimonidazole derived hypoxic fractions and
the mean FMISO signal intensity, but also noticed that
the correlation varied between the tumour lines stressing
the need for validation in clinical studies with different
tumour entities (Fig. 4). Furthermore they observed that
in the registration of changes of oxygenation status,
FMISO was less accurate as the reference pimonidazole.
Temporal changes-treatment induced changes
Little is known about the temporal stability of hypoxia
imaging, and there are at least three aspects to consider.
First, hypoxia can be transient due to structural and
functional abnormalities of the tumour microvessels [55].
These abnormalities cause disturbances in the blood
supply leading to temporal shutdown of vessels [55–57].
So, areas identified as ‘normoxic’ could be ‘hypoxic’
at a different time point. These changes occur at
the microregional level and little is known about the
sensitivity of PET-scanning for such changes. Second,
the lifetime of chronically hypoxic cells is short, varying
from a few hours to several days [58,59]. By the time
radiation treatment commences, the hypoxic cells that
were imaged will have already died and be replaced.
Although the lifetime of individual cells is short, it is
unlikely that the overall hypoxic pattern of a tumour will
change significantly in a period of a few days. However, if
intervals between PET imaging and treatment exceed one
or two weeks, this may become a relevant problem. Third,
irradiation itself can cause rapid changes in oxygenation
and perfusion [60].
So even if the information obtained by functional
imaging correlates with a relevant tumour characteristic,
and even if that characteristic has an impact on clinical
decision making on treatment selection, one has to be
aware that the temporal stability of the imaged data may
be limited. Currently, studies of temporal stability of
hypoxia maps are in progress.
Can intratumoural biological
heterogeneity be identified?
Concept of dose painting
The concept of dose painting was proposed by Ling
et al. [2]. The idea is to visualize tumour subvolumes with
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Figure 4 FMISO autoradiography (A), pimonidazole immunohistochemistry (B) and fusion image (C) of a
xenografted human head and neck cancer. Courtesy of E. Troost, Department of Radiation Oncology, Radboud
University Nijmegen Medical Centre, Nijmegen, The Netherlands.
a potential resistance to irradiation and to paint some
additional dose onto that volume. Chao et al. [61] applied
this in a pilot study demonstrating an IMRT plan where
a subvolume of the oropharyngeal tumour, identified by
increased 64Cu-ATSM retention, received an extra dose
of 10 Gy. Despite the dose escalation in this dose painting
exercise the parotid glands could still be adequately
spared with the high precision IMRT technique.
Spatial resolution
At the level of the tumour microenvironment, it is
conceivable that new cells formed in the proliferating
cell compartment push older cells away from the blood
vessels resulting in a gradual depletion of oxygen and
nutrients. Tumour cells in the hypoxic compartment
would be pushed further down the oxygen gradient and
eventually die of oxygen deficiency and starvation [62].
The dynamics of hypoxic tumour cells in xenografted
human head and neck cancer was analysed by consecutive
injection of two different hypoxia markers [59]. Over time,
pimonidazole positive cells were being pushed away
from the vasculature and cell debris with pimonidazole
adducts appeared in the necrotic regions. Meanwhile, new
hypoxic cells appeared at the ‘hypoxic front’ identified
by a second marker, CCI-103F, administered at a later
point in time. This ‘pattern of hypoxia’ is measured in
micrometres and therefore cannot be detected by in vivo
imaging techniques such as PET due to limited spatial
resolution. So PET images hypoxia at a more global
level. Furthermore the radiation dose delivery also has a
certain resolution. Given these limitations, dose painting
will most likely only be feasible with subvolumes greater
than 0.5 cm3. PET imaging would then have to identify
subvolumes within the tumour with a larger than average
content of hypoxic cells.
Conclusion
Integrating biological or molecular information of
tumours into radiation oncology might help in deciding
not only where but also how radiation therapy should be
delivered [63]. The addition of functional imaging to the
standard anatomically based target volume definition has
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already shown significant advantages, especially when
images are co-registered. The reduction of interobserver
variability is obvious and can increase the standard of
care for all patients, not only by reducing geographically
missing parts of the cancer, but also by reducing the
irradiated volume of normal tissues and organs at risk.
As more studies become available validating the
various functional imaging properties, more treatment
related decisions (dose painting, shortening overall
treatment time, adding a sensitizer) will have to be
tested in clinical trials. The goals are challenging
and clear: first, to enlarge the therapeutic window by
increasing the tumour control probability and decreasing
the normal tissue complication probability; second, to
develop predictive assays that can serve as selection
tools for patients that are likely to profit from intensified
treatments. We believe that molecular imaging can play
an important role in achieving these goals.
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